Advanced Glycation Endproducts: A Marker of Long-term Exposure to Glycemia
Journal of Diabetes Science and Technology · 2025
DOI: 10.1177/19322968241240436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Diabetes Science and Technology, 2025. Verfasst von David C Klonoff und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, Blood Glucose, Diabetes Mellitus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, NIA NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
This article examines the importance of advanced glycation endproducts (AGEs) and summarizes the structure of AGEs, pathological changes associated with AGEs, the contribution of AGEs to metabolic memory, and the value of AGEs as a predictor of diabetic complications and cardiovascular disease in people with and without diabetes. As a practical focus, skin autofluorescence (SAF) is examined as an attractive approach for estimating AGE burden. The measurement of AGEs may be of significant value to specific individuals and groups, including Black and Hispanic/Latino Americans, as they appear to have higher concentrations of hemoglobin A 1c (HbA 1c ) than would be predicted by other metrics of mean glycemia. We hypothesize that if the amount of glycation of HbA 1c is greater than expected from measured glucose levels, and if AGEs are accumulating, then this accumulation of AGEs might account for the increased rate of complications of diabetes in populations with high rates of vascular disease and other complications. Thus, identifying and modifying the burden of AGEs based on measurement of AGEs by SAF may turn out to be a worthwhile metric to determine individuals who are at high risk for the complications of diabetes as well as others without diabetes at risk of vascular disease. We conclude that available evidence supports SAF as both a clinical measurement and as a means of evaluating interventions aimed at reducing the risks of vascular disease and diabetic complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, CA, USA.
- Diabetes Technology Society, Burlingame, CA, USA.
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- VA Greater Los Angeles Healthcare System, UCLA, Los Angeles, CA, USA.
- Kinexum, Harpers Ferry, WV, USA.
- National Institutes of Health, Bethesda, MD, USA.
ORCID-Profile: David C Klonoff, Rachel E Aaron, Tiffany Tian, Ashley Y DuNova, Ambarish Pandey, G Alexander Fleming, David B Sacks, Rodica Pop-Busui, David Kerr
Förderung
- NIMHD NIH HHS
- NIA NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Klonoff, D. C., Aaron, R. E., Tian, T., DuNova, A. Y., Pandey, A., Rhee, C., Fleming, G. A., Sacks, D. B., Pop-Busui, R., & Kerr, D. (2025). Advanced Glycation Endproducts: A Marker of Long-term Exposure to Glycemia. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968241240436
Vancouver
Klonoff DC, Aaron RE, Tian T, DuNova AY, Pandey A, Rhee C, et al. Advanced Glycation Endproducts: A Marker of Long-term Exposure to Glycemia. Journal of Diabetes Science and Technology. 2025. doi:10.1177/19322968241240436
BibTeX
@article{Klonoff2025,
author = {Klonoff, David C and Aaron, Rachel E and Tian, Tiffany and DuNova, Ashley Y and Pandey, Ambarish and Rhee, Connie and Fleming, G Alexander and Sacks, David B and Pop-Busui, Rodica and Kerr, David},
title = {Advanced Glycation Endproducts: A Marker of Long-term Exposure to Glycemia},
journal = {Journal of Diabetes Science and Technology},
year = {2025},
doi = {10.1177/19322968241240436}
}
EUVIMED